How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Pharmaceutical Retail Chain Market
- By Store Format: Standalone Pharmacy, Chain Pharmacy Store, Supermarket Pharmacy Section, Hospital Pharmacy, Online Pharmacy
- By Product Category: Prescription Drugs, Over-the-Counter (OTC) Medicines, Health and Wellness Products, Personal Care Products, Medical Devices and Supplies
- By Customer Segment: General Consumers, Chronic Disease Patients, Elderly Population, Pediatric Patients, Healthcare Professionals
- By Distribution Channel: Brick-and-Mortar Stores, E-commerce Platforms, Mobile Pharmacy Apps, Home Delivery Services
- By Ownership Model: Company-Owned Stores, Franchise Stores, Independent Pharmacies
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Standalone Pharmacy leads By Store Format at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 9 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 284 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.181 →
- 12 Company Profiles 9 players: SWOT & benchmarking p.189 →
Full report · locked preview
Everything inside the Pharmaceutical Retail Chain Market report
A complete, evidence-based study - 12 chapters and 119 sections covering market size, segmentation across 5 axes, regional analysis and 9 company profiles, forecast to 2033.
Segmentation covered
Store Format 5
Product Category 5
Customer Segment 5
Distribution Channel 4
Ownership Model 3
Companies profiled
CVS Health
Walgreens Boots Alliance
Cencora (formerly McKesson Corporation)
Rite Aid Corporation
Boots UK (part of Walgreens Boots Alliance)
Walmart Pharmacy
LloydsPharmacy (part of McKesson Europe)
Shoppers Drug Mart (part of Loblaw Companies)
Phoenix Group
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
9 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →CVS Health
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Walgreens Boots Alliance
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Cencora (formerly McKesson Corporation)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Rite Aid Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Boots UK (part of Walgreens Boots Alliance)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.178 →Walmart Pharmacy
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →LloydsPharmacy (part of McKesson Europe)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Shoppers Drug Mart (part of Loblaw Companies)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.196 →Phoenix Group
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.202 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$4,836M by 2033 · 10.9% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Standalone Pharmacy59.9
- Chain Pharmacy Store7.6
- Supermarket Pharmacy Section6.7
- Hospital Pharmacy9.4
- Online Pharmacy16.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$695.9M → $1,588M · 10.9%
Europe$485.1M → $1,114M · 10.9%
Asia Pacific$442.9M → $1,075M · 11.7%
Latin America$274.2M → $650.7M · 11.4%
Middle East and Africa$210.9M → $459.9M · 10.2%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.892026
10.912027
10.912028
10.932029
10.942030
10.952031
10.962032
10.972033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- CVS Health30.8
- Walgreens Boots Alliance9.6
- Cencora (formerly McKesson Corporation)9.5
- Rite Aid Corporation4.5
- Boots UK (part of Walgreens Boots Alliance)8.2
- Walmart Pharmacy9.3
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Store Format23.3%
Product Category23.5%
Customer Segment18.3%
Distribution Channel13.5%
Ownership Model21.4%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.5
- Europe22.8
- Asia Pacific22.0
- Latin America13.3
- Middle East and Africa9.4
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| CVS Health | 87 | 97 | 98 | 74 | 82 | 88 | 88 |
| Walgreens Boots Alliance | 79 | 74 | 76 | 69 | 91 | 72 | 77 |
| Cencora (formerly McKesson Corporation) | 70 | 80 | 63 | 86 | 84 | 85 | 78 |
| Rite Aid Corporation | 66 | 72 | 59 | 81 | 65 | 74 | 70 |
| Boots UK (part of Walgreens Boots Alliance) | 75 | 61 | 54 | 74 | 71 | 76 | 69 |
| Walmart Pharmacy | 53 | 63 | 61 | 62 | 48 | 58 | 58 |
| LloydsPharmacy (part of McKesson Europe) | 46 | 64 | 50 | 46 | 49 | 64 | 53 |
| Shoppers Drug Mart (part of Loblaw Companies) | 35 | 42 | 53 | 49 | 53 | 58 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- CVS Health
- Walgreens Boots Alliance
- Cencora (formerly McKesson Corporation)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| CVS Health | ✓ | ✓ | ✓ | ✓ | ◐ | ✓ |
| Walgreens Boots Alliance | ◐ | ✓ | ◐ | ◐ | ✓ | − |
| Cencora (formerly McKesson Corporation) | ◐ | ✓ | ◐ | ✓ | ✓ | ✓ |
| Rite Aid Corporation | ◐ | − | ◐ | ◐ | − | ✓ |
| Boots UK (part of Walgreens Boots Alliance) | ◐ | ◐ | − | ◐ | ◐ | ◐ |
| Walmart Pharmacy | ◐ | − | ◐ | ◐ | − | − |
| LloydsPharmacy (part of McKesson Europe) | − | − | − | − | − | ◐ |
| Shoppers Drug Mart (part of Loblaw Companies) | − | − | ◐ | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1CVS Health88
2Cencora (formerly McKesson Corporation)78
3Walgreens Boots Alliance77
4Rite Aid Corporation70
5Boots UK (part of Walgreens Boots Alliance)69
6Walmart Pharmacy58
7LloydsPharmacy (part of McKesson Europe)53
8Shoppers Drug Mart (part of Loblaw Companies)48
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
CVS HealthCencora (formerly McKesson Corporation)
Challenger3
Strong scale, closing on the leaders.
Walgreens Boots AllianceRite Aid CorporationBoots UK (part of Walgreens Boots Alliance)
Contender1
Focused players with pockets of strength.
Walmart Pharmacy
Niche2
Specialists in a single segment or region.
LloydsPharmacy (part of McKesson Europe)Shoppers Drug Mart (part of Loblaw Companies)
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Store Format in North America, then scale across Pharmaceutical Retail Chain Market — a $347M beachhead inside a $6.11B market.
Beachhead (SOM)$347Mobtainable near-term
Serviceable (SAM)$2.15Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
Standalone Pharmacy
Best fit — highest urgency & budget in Store Format.
Economic buyer80 fit
Chain Pharmacy Store
Strong fit — clear ROI and a fast path to value.
End user66 fit
Supermarket Pharmacy Section
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Store Format in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Product Category & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Customer Segment
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel27%
Digital / self-serve21%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Store Format leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Pharmaceutical Retail Chain Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified46%
Sales qualified23%
Evaluation13%
Closed-won7%
$18.0KCAC
$108KLTV
6.0:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Pharmaceutical Retail Chain Market is a high-growth opportunity — $5.46B by 2033, compounding at 11.0%.
TAM · 2025$2.36Btoday
TAM · 2033$5.46Bforecast
CAGR11.0%2027–2033
Cumulative$33.5Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$5.46BTotal addressable market
SAM$2.24BServiceable available market
SOM$412MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →11.0% CAGR
Demand compounds through 2033, outpacing GDP across Store Format.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Store Format moving from early to mainstream — durable secular demand.
Consolidation upside
9+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$5.46BLarge & growingTAM by 2033 at 11.0% CAGR
$2.24BServiceable nowreachable with today’s model
$412MBeachhead winobtainable near-term share
9+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.26BBear7.2% CAGR
$5.46BBase11.0% CAGR
$6.99BBull14.6% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Product Category optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Pharmaceutical Retail Chain Market — a $1.80B market by 2033. Plan: grow share from 7.9% to 17.0%.
Market size · 2033$1.80Btotal addressable
Market CAGR7.0%2027–2033
Target share17.0%from 7.9% today
Revenue ambition$306Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.9% | 17.0% | Behind |
| Revenue | $139M | $306M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 36.4% | 38.2% | On track |
| Customer retention | 91.1% | 93.9% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Store Format
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Product Category capability
A defensible second engine — invest in Product Category to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Store Format share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Product Category
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $44M capacity & capability investment
- Greenlight bolt-on M&A in Product Category
- Authorise North America expansion plan
- Fund R&D program for Store Format leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAt risk
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Pharmaceutical Retail Chain Market conversation — a $5.51B market you can size, segment and defend in minutes.
Market size · 2033$5.51Btotal opportunity
Growth9.5%CAGR to 2033
Addressable buyers1,204+accounts in scope
Typical ROI6.7×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Store Format
Goal Grow share in Store Format
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.7×return on cost, year one
< 2 mopayback period
$84K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
9+players profiled in this market
Coverage includes
CVS HealthWalgreens Boots AllianceCencora (formerly McKesson Corporation)Rite Aid CorporationBoots UK (part of Walgreens Boots Alliance)Walmart PharmacyLloydsPharmacy (part of McKesson Europe)Shoppers Drug Mart (part of Loblaw Companies)+1 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Pharmaceutical Retail Chain Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Pharmaceutical Retail Chain Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Pharmaceutical Restricted Access Barrier Systems (RABS) Market
Pharmaceutical Restricted Access Barrier Systems (RABS) Market is valued at USD 520 Million in …
$520M market · 2025 base year
View reportPharmaceutical Restricted Access Barrier Systems Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportPharmaceutical Release Testing Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportPharmaceutical Regulatory Affairs Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportPharmaceutical Refrigerators with Freezer Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportPharmaceutical Refrigerators Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportPharmaceutical Refrigerated Warehousing Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportPharmaceutical Raw Material Testing Service Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportPharmaceutical Quality Management Software Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportPharmaceutical Quality Control Testing Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportPharmaceutical PVC High Barrier Film Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportPharmaceutical PVC Film Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.